Int J Urol: Impact of neoadjuvant chemotherapy on survival and recurrence patterns in patients after robotic-assisted radical cystectomy

Bladder cancer is the sixth most common malignancy in the United States, with more than 80,000 new cases and 17,000 deaths in 2019
.

Nearly a quarter of patients had muscle-invasive disease (clinical stage ≥T2)

A Phase III randomized clinical trial SWOG-8710 demonstrates the benefit of NAC iMIBC in which MVAC improves OS A phase III randomized clinical trial SWOG-8710 demonstrates the benefit of NAC iMIBC in which MVAC improves OS

Recently, researchers from the United States published an article in "Int J Urol" to analyze the effect of neoadjuvant chemotherapy on the survival and recurrence patterns of patients with muscle-invasive bladder cancer after robotic-assisted radical cystectomy
.

To analyze the effect of neoadjuvant chemotherapy on the survival and recurrence patterns of patients with muscle-invasive bladder cancer after robotic-assisted radical cystectomy.
Effects of survival and recurrence patterns

Using the International Robotic Cystectomy Consortium database, researchers identified patients with muscle-invasive bladder cancer who underwent robotic-assisted radical cystectomy between 2002 and 2019
.

Survival outcomes, response rates, and recurrence patterns were compared between patients who received neoadjuvant chemotherapy and those who did not

A total of 1370 patients with muscle-invasive bladder cancer were included in the study, of whom 353 (26%) received neoadjuvant chemotherapy
.

After a median follow-up of 27 months, 3-year overall survival (74% vs 57%; log-rank P<0.

Kaplan–Meier assessment of OS and RFS in NAC versus non-NAC patients

Kaplan–Meier assessment of OS and RFS in NAC versus non-NAC patients

In conclusion, patients with muscle-invasive bladder cancer who received neoadjuvant chemotherapy before robotic-assisted radical cystectomy had higher survival rates, higher rates of pathological de-escalation and negative resection margins, and fewer distant recurrences

Patients with muscle-invasive bladder cancer who received neoadjuvant chemotherapy before robotic-assisted radical cystectomy had higher survival, rate of pathological de-escalation, and rate of negative resection margins, and fewer distant recurrences than robotic-assisted radical cystectomy Patients with muscle-invasive bladder cancer who previously received neoadjuvant chemotherapy had higher rates of survival, rate of pathologic de-escalation, rate of negative resection margins, and fewer distant recurrences

Original source:

Original source:

Dharmesh Gopalakrishnan, Ahmed S Elsayed, Ahmed A Hussein et al.

Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium

 

leave a message here